RegeneRx Biopharmaceuticals, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, CohnReznick LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | 0.00% | 0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11K | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+53.61% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-15.71% | 11.89B | |
-42.56% | 11.61B | |
+4.72% | 8.84B |
- Stock Market
- Equities
- RGRX Stock
- News RegeneRx Biopharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt